Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は Mexico City, DF, Mexico. 現CEOは Juan Marco Sparvieri.
GNMLF を有する IPO日 2012-05-04, 1,605 名の正社員, に上場 Other OTC, 時価総額 $1.05B.
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
